Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mission: Ongoing! China Looks To Align With FDA In Landmark IND Push

Executive Summary

Issuing new guidance for INDs, doubling reviewers, adopting priority and accelerated reviews, and cutting a submission backlog are among the raft of measures the China FDA is quietly but assertively taking to accelerate new drug approvals and support innovation.


Related Content

Bring On Clinical Studies: China Steps Up To Facilitate New Drug Entry
China Keeping Eye On Key Regulatory Dialog After Trump Win
Withdrawals Slash CFDA’s 2015 Approval Numbers


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts